Mint Explainer | First Dr Reddy’s, now Natco: Why Indian drugmakers are suing Novo Nordisk

As the patent for semaglutide nears its end, Novo Nordisk’s dominance in the weight-loss market is being challenged. The lawsuits could pave the way for cheaper generics, catering to India’s vast population battling obesity. 

​As the patent for semaglutide nears its end, Novo Nordisk’s dominance in the weight-loss market is being challenged. The lawsuits could pave the way for cheaper generics, catering to India’s vast population battling obesity.